Abstract
The management of noninfectious uveitis (NIU) has involved the use of corticosteroids and immunomodulators (IMT). However, a certain subset of NIU patients does not respond to conventional IMT therapy, such as methotrexate and azathioprine. In these patients, biological IMT with specific targets is employed. One such example is the use of TNF-α inhibitors, such as adalimumab and infliximab. These biologics target specific inflammatory cytokines, unlike the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signaling pathway. JAK-STAT inhibitors (JAKinibs) are classified as targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs), which are small-molecule drugs that are chemically synthesized rather than biologically derived. In contrast to biologic DMARDs or bDMARDs, tsDMARDs are smaller molecules that are orally available, nonimmunogenic, and capable of crossing the cell membrane. JAKinibs can simultaneously block multiple cytokine-signalling pathways, such as those driven by IL-6, IL-12, IL-23 and IL-17, as they dampen Th1- and Th17-driven inflammation. This ability to target a broad range of inflammatory cytokines and immune pathways theoretically enables JAKinibs to be viable alternatives for the treatment of NIU resistant to conventional IMT and biologicals. JAK-STAT inhibitors, such as tofacitinib, baricitinib, upadacitinib, peficitinib, delgocitinib, and filgotinib have been FDA-approved for use in autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and inflammatory bowel disease. The available literature suggests the potential efficacy of these drugs in controlling uveitic inflammation; however, their use in NIU is still under investigation, with no randomized controlled trials providing Level I evidence.
Keywords: JAK inhibitors, JAK-STAT, noninfectious uveitis, tofacitinib, uveitis
The exact etiology and pathogenesis of noninfectious uveitis (NIU) are not well-understood; however, several inflammatory pathways appear to be associated with NIU. The mainstay of acute NIU management involves suppressing inflammation through corticosteroid therapy, but long-term use is inappropriate due to the associated side effects. In patients with a relapsing and remitting course, long-term therapy with steroid-sparing agents, such as immunomodulators (IMT), becomes imperative. Similarly, a subset of patients with NIU may not have an adequate response to corticosteroids, requiring a stepladder approach with newer therapeutic options such as IMT and biologicals.
Cytokines play a central role in the pathogenesis of inflammation and have been used as therapeutic targets in controlling uveitis and other inflammatory disorders. This has been successfully achieved with monoclonal antibodies against specific cytokines, such as adalimumab (Ada) against tumor necrosis factor-alpha (TNF-α), or their receptors, such as tocilizumab against the IL-6 receptor. Janus kinases (JAKs) are multidomain, nonreceptor tyrosine kinases that serve as key intracellular components of cytokine signaling. Cytokines, in turn, are pivotal in many essential cellular functions, including the pathogenesis of immunological diseases, either through their normal functions or due to deregulation. All cytokines are associated with one or more of the JAKs as part of their signaling pathway. In humans, the JAK family consists of JAK1, JAK2, JAK3, and TYK2. This signaling cascade is initiated by the binding of a cytokine to its receptor, leading to the activation and transphosphorylation of JAKs. This, in turn, induces the recruitment, dimerization, and nuclear translocation of signal transducer and activator of transcription (STAT), ultimately resulting in transcriptional responses.[1] In summary, by inhibiting specific JAK enzymes, JAK-STAT inhibitors (JAKinibs) block the downstream activation of STAT proteins, thereby reducing cytokine production, which subsequently dampens Th1- and Th17-driven inflammation—forming the basis of their role in NIU [Fig. 1].[2] As individual cytokine receptors recruit their own combination of JAKs to initiate distinct processes in targeted cells, targeting a specific JAK can antagonize more than one cytokine pathway, thus expanding therapeutic efficacy.[1] Furthermore, monoclonal antibodies against cytokines, such as Ada (anti TNF-α), are effective in only 40%–60% cases,[3,4] and their efficacy is limited by the formation of antidrug antibodies.[5] Besides targeting a wide array of cytokines, JAKinibs are nonimmunogenic, small molecules that can be orally administered, thereby reducing the number of visits to healthcare facilities.[6] Animal models have shown that JAKinibs, such as tofacitinib, inhibit the development of experimental autoimmune uveitis (EAU) and decrease the production of INF-γ, while upadacitinib has demonstrated therapeutic efficacy in the treatment of EAU.[7,8] Suppressor of cytokine signaling (SOCS) proteins, such as SOCS1 and SOCS3, bind to JAK kinases and prevent their activation in experimental autoimmune uveitis.[9,10] The results of these studies may be extrapolated to the treatment of NIU. A systematic review of 7 studies involving 11 patients, primarily consisting of case reports and case series, has demonstrated the utility of JAKinibs in autoimmune uveitis.[11] Recently, clinical trials and research have focused on targeting the JAK-STAT pathways to manage a wide array of diseases using JAK inhibitors. Currently available FDA-approved JAKinibs include tofacitinib, upadacitinib, abrocitinib, ruxolitinib, baricitinib, ritlecitinib, fedratinib, pacritinib, deucravacitinib, and momelotinib for various autoimmune indications.[12] Drugs such as filgotinib are approved in Europe and Japan, while peficitinib is approved for use in Japan only.[12]
Figure 1.

Summary of mechanism of action of JAK-STAT and its inhibitors on Immune response
In this review, we aim to summarize the available literature on JAKinibs used in uveitis for practicing clinicians.
Method of Literature Review
A literature search was conducted on PubMed/Medline, Scopus, and Web of Science using the key words “JAK-STAT inhibitors, tofacitinib, upadacitinib, abrocitinib, ruxolitinib, baricitinib, ritlecitinib, fedratinib, pacritinib, deucravacitinib, momelotinib, filgotinib, peficitinib, brepocitinib” in combination with the Boolean operator “AND” and the keywords “noninfectious uveitis, relapsing uveitis, refractory uveitis.” Original studies and novel observations regarding the use of JAKinibs in treating rheumatological diseases associated with uveitis in adults and children were included. Additionally, references from the selected articles were reviewed to further expand the literature search. The included articles were then assessed in detail to document the clinical presentation and management, with an emphasis on efficacy and side effects in these cases.
Use of available Jak Kinase inhibitor in Uveitis: A literature review
JAKinibs represent a rapidly expanding category of medications, accompanied by a growing body of research. Although primarily used for rheumatoid arthritis and psoriatic arthritis, multiple phase 2 and 3 trials are underway to determine the efficacy and safety in various inflammatory and hemato-oncological disease states. In contrast, the use of JAKinibs in uveitis has been largely limited to case reports and case series, primarily in patients refractory to conventional IMT, where they have been used as third- or fourth-line agents. Based on these reports, authors have described the role of JAKinibs in juvenile idiopathic arthritis (JIA)-associated uveitis.[13] A multicenter phase 3 trial (JUVE-BRIGHT) is currently evaluating the role of baricitinib in JIA with uveitis or chronic ANA-positive uveitis that is refractory to topical steroids and methotrexate (MTX) but not biologics. This study evaluates an Ada active reference arm to compare efficacy and will also assess the safety profile of baricitinib in study participants.[14] The available literature on the use of various JAKinibs in uveitic conditions is summarized in Table 1.
Table 1.
Summary of available literature on JAKinibs in uveitis
| Authors | Type of Study | Indication of JAKinib | JAKinib used | Primary endpoint | Number of Patients | Result | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Paley et al., 2019[15] | Case report | NIU and scleritis refractory to/intolerant to conventional IMT | Tofa | Efficacy | 2 | Resolution of inflammation in Patient 1 with NIU with tofa 11 mg extended-release, with additional MTX, which was discontinued later. Patient 2, with refractory scleritis, was controlled with tofa 11 mg extended-release + MTX | ||||||
| Bauermann et al., 2019[16] | Case report | JIA refractory to multiple IMT | Tofa | Efficacy | 1 | Resolution of inflammation on tofa 5 mg BD + MTX 2.5 mg on alternate day | ||||||
| Fabiani et al., 2020[17] | Case report | Diffuse bilateral anterior scleritis with RA | Tofa initated for RA | Efficacy | 1 | Resolution of scleritis on tofa 5 mg BD with 5 mg prednisolone at 6 months of follow-up | ||||||
| Miserocchi et al., 2020[18] | Monocentric, Case Series | JIA refractory to anti-TNF-α Agents | Bari and Tofa | Efficacy | Tofa: 1 patient Bari: 3 patients |
Patient 1 was treated with tofa for arthritis control, while uveitis remained inactive. Patients 2,3, and 4 were treated with bari for both arthritis and uveitis control. JAKinibs were effective in resolving ocular features, but systemic features persisted. |
||||||
| Pyare et al., 2020[19] | Case report | Scleritis refractory to conventional IMT | Tofa | Efficacy | 1 | Tofa 5 mg BD, in addition to MMF 1000 mg BD, was effective in controlling scleritis | ||||||
| Dutta Majumder et al., 2020[20] | Case report | Non- resolving VKH despite high dose intravenous and oral steroids. | Tofa | Efficacy | 1 | Tofa 10 mg/day was effective in resolving inflammation and SRF at 1 month of therapy, with tapering of oral corticosteroid therapy. | ||||||
| Sejournet et al., 2021[21] | Case report | Panuveitis and mediastinal sarcoidosis with RA | Tofa | Efficacy | 1 | RA with sarcoidosis, manifesting as mediastinal lymphadenopathy and panuveitis, responded to tofa 5 mg BD. | ||||||
| Kaneko et al., 2021[22] | Case report | RA related panuveitis refractory to combination of MTX, ADA and MTX, IFX | Bari | Efficacy | 1 | Bari 8 mg/day was effective in controlling both systemic and ocular features of inflammation | ||||||
| Xiao-Bao Liu et al., 2022[23] | Case Report | Non-infectious idiopathic chronic anterior uveitis | Tofa | Efficacy | 1 | Noninfectious uveitis with no systemic features, previously treated with systemic corticosteroids, biologics, and conventional IMT, responded to tofa 5 mg BD | ||||||
| Pyare et al., 2022[24] | Monocentric, retrospective, Case series | Scleritis refractory to conventional IMT | Tofa | Efficacy | 9 | In a diverse group of patient refractory to multiple IMT agents, tofa was effective in controlling inflammation. Adverse events: one patient experienced reactivation of herpetic keratitis. | ||||||
| Baisya et al., 2022[25] | Case Report | SAPHO with uveitis | Tofa | Efficacy | 1 | Tofa 5 mg BD was effective | ||||||
| Álvarez-Reguera et al., 2022[26] | Case report | Sporadic Blau refractory to multiple IMT/biologics including ADA | Tofa and Bari | Efficacy and safety | 1 | Tofa 5 mg BD successfully induced remission but led to refractory lymphopenia (ALC=700 cells/μl). It was subsequently replaced with bari 4 mg daily, which continued to suppress the disease, though another episode of lymphopenia occurred after 4 months of therapy (ALC=800 cells/μl) | ||||||
| Wang et al., 2022[27] | Case report | BD | Tofa | Efficacy | 1 | Tofa extended-release 11 mg was effective in resolving systemic and ocular features of BD refractory to MTX and colchicine | ||||||
| Schneider et al., 2022[28] | Case report | IU secondary in HLA B27 positive patient refractory to steroids + ADA | Upada | Efficacy | 1 | Upada 15 mg/day was sufficient to induce and maintain remission while tapering oral steroids | ||||||
| Babu K et al.,2022[29] | Case Report | Polyarticular JIA with Chronic anterior uveitis | Tofa | Efficacy | 1 | Tofa 5 mg BD combined with MTX 15 mg/week was sufficient to induce and maintain remission while tapering oral steroids | ||||||
| Wang et al., 2023[30] | Pilot study | BD with refractory vascular involvement | Bari | Efficacy and safety | 17 total, 1 with uveitis | Bari was effective in reducing disease activity, with no serious adverse effects noted | ||||||
| Tao et al., 2023[31] | Case report | Macular edema associated with BD refractory to Anti TNF-α combined with MTX, MMF, CsA therapy | Upada | Efficacy | 2 | Ada was replaced with upada in the treatment regimen, leading to effective and maintained remission. One patient developed transient mild leukopenia and transaminitis but recovered with herbal treatment. | ||||||
| Baquet-Walscheid et al., 2023[32] | Case report | JIA with macular edema refractory to multiple IMT, biologics, and tofa 11 mg/day | Upada | Efficacy | 1 | Upada 15 mg/day was effective in inducing remission of both ocular and systemic inflammation, within 2 weeks of therapy initiation. Remission was maintained on Upada monotherapy after 4 months, with prednisolone 1% OD in the right eye. | ||||||
| Dey et al., 2023[33] | Case series | Scleritis refractory to conventional IMT | Tofa | Efficacy | 3 | Tofa 5 mg twice daily was effective in inducing remission in all three patients. | ||||||
| Baquet-Walscheid et al., 2024[34] | Case report | Non necrotizing bilateral anterior and posterior scleritis | Upada | Efficacy | 1 | Upada was effective in controlling systemic and ocular inflammation after 1 week of monotherapy. | ||||||
| Vitale et al.,2024[35] | Prospective cohort study | Non-infectious ocular inflammatory disease from the Autoinflammatory Disease Alliance (AIDA) | Tofa (n=1) Bari (n=4) Upada (n=7) |
Ocular flares, visual acuity, disease course before and after JAKinibs therapy | 12 | Underlying systemic disease was seen in eight patients. Ocular disease control was achieved in all 12 patients, with an overall average duration of JAKinibs treatment of 8.6±5.5 months (ranging from 3 to 20 months). The incidence of ocular flares prior to initiation of JAKinibs was 125 episodes/1,000 person-months, which decreased to 28.6 episodes/1,000 person-months following initiation of JAKinibs. | ||||||
| Majumder et al., 2024[36] | Case Series | Treatment resistant uveitis and scleritis in pediatric patients | Tofa | Efficacy | 9 | Tofa 5 mg BD was effective in controlling ocular inflammation, with no side effects noted despite a median follow-up of 277.5 days | ||||||
| Srivastava et al., 2024[37] (HUMBOLDT) | Prospective Randomized Control trial | Treatment of active non-infectious intermediate uveitis, posterior uveitis and panuveitis despite 2-weeks of systemic corticosteroid therapy | Filgotinib | Efficacy and Safety | 74 (38 on Filgotinib, 36 on Placebo) | Treatment failure at 24 weeks of therapy with filgotinib was 37.5% v/s 67.6% in patients receiving placebo. Adverse events were reported in 30/37 (81.8%) participants receiving filgotinib, compared to 24/35 (68.6%) participants receiving placebo. Serious adverse events were reported in 13.5% of the filgotinib group, compared to 5.7% was reported in the placebo group. |
ADA=Adalimumab, ALC=absolute lymphocyte count, Bari=Baricitinib, BD=Behcet’s disease, IFX=Infliximab, IMT=immunomodulatory therapy, IU=Intermediate uveitis, JIA=Juvenile idiopathic arthritis, MMF=Mycophenolate mofetil, MTX Methotrexate, NIU=Non-infectious uveitis, RA=rheumatoid arthritis, SAPHO=synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome, SRF=subretinal fluid, Tofa=Tofacitinib, Upada=Upadacitinib, VKH=Vogt- Koyanagi Harada
Tofacitinib
Tofacitinib is a small molecule that reversibly inhibits JAK, particularly JAK1 and JAK3,[38] thereby blocking the activity of IL-2, IL-4, IL-15, and IL-21. Tofacitinib is FDA-approved for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and polyarticular course JIA (pcJIA).[39,40,41,42,43] Isolated case reports on the use of tofacitinib in ulcerative keratitis and mucous membrane pemphigoid have been published as early as 2014.[11] In uveitis, Paley et al.[15] first reported the use of tofacitinib in a case of HLA-B27-positive NIU that was refractory to and intolerant to conventional IMT, including MTX, leflunomide, azathioprine (Aza), and mycophenolate mofetil (MMF), as well as fluocinolone acetonide implants. AntiTNF-α agents were effective but not tolerated due to administration-related side effects such as infusion reactions, injection site reactions, and recurrent infections. The ocular symptoms improved with a combination of tofacitinib 11 mg extended-release tablets and MTX, although systemic signs worsened once MTX was discontinued. The authors also reported the resolution of symptoms with the same combination in a case of scleritis that was refractory to MTX and MMF as monotherapy, intolerant to Aza due to recurrent cutaneous and enteric ulcers, and associated with kidney dysfunction (hematuria) following oral cyclophosphamide treatment. Subsequently, Bauermann et al.,[16] described the use of JAKinibs in refractory JIA with macular edema in an adult patient, who had failed to respond to MTX, Ada, rituximab, golimumab, infliximab, cyclosporine, tocilizumab, and MMF. Local corticosteroid therapy, in the form of dexamethasone (700 µg) implants, provided temporary resolution of ME. The patient ultimately responded to tofacitinib 5 mg twice daily combined with 2.5 mg oral MTX every other day. Miserocchi et al.[18] reported four cases of JIA refractory to biologic therapy that responded to baricitinib or tofacitinib. Pyare et al.[19] reported a case of scleritis refractory to systemic corticosteroid (1 mg/kg/day) with MMF monotherapy, which subsequently responded to the addition of tofacitinib 5 mg twice daily. The same group also published a case series on the use of tofacitinib in scleritis, in which they reported the administration of tofacitinib 5 mg twice daily alongside conventional IMT. The addition of tofacitinib helped control symptoms and reduced the required dosage of steroids required for maintenance therapy. The only adverse effect noted was the reactivation of herpetic keratitis in two patients following 1 month of tofa therapy. These patients were successfully managed with antiviral treatment.[24] Dutta Majumder et al.[20] reported a case of Vogt–Koyanagi–Harada (VKH) disease that was refractory to high-dose corticosteroids, with exudative retinal detachment persisting despite five doses of intravenous methylprednisolone (1 g/day), followed by high-dose oral steroids (80 mg/day). Subsequently, tofacitinib 10 mg/day was initiated, leading to a rapid resolution of subretinal fluid within 1 month, allowing for the tapering of oral steroids. This case report highlights the role of JAKinibs as an add-on IMT therapy to systemic corticosteroids, with an onset of action observed within 4 weeks of therapy. Liu et al. have evaluated the role of JAKinibs, such as tofacitinib, in the treatment of VKH using single-cell RNA and mass cytometry to understand how tofacinib alters immune cell activity in VKH.[44] Dutta Majumder et al.[36] also reported the use of tofacitinib in pediatric patients with treatment-resistant uveitis and scleritis, demonstrating good efficacy.
The possible role of tofacitinib in pediatric patients with Blau syndrome has also been explored by Zhang et al.[45] Although none of the three patients in their series had uveitis, all three exhibited systemic manifestation of arthritis, which responded well to tofacitinib without any serious adverse effects reported during a follow-up duration of more than four months. Álvarez-Reguera et al.[26] reported a case of sporadic Blau that was refractory to multiple conventional IMT therapy and biologic, including MTX, etanercept, anakinra, abatacept, and adalimumab. The patient ultimately responded to tofacitinib 5 mg twice daily, with improvements in anterior uveitis and macular edema observed within the first few weeks of therapy. Unfortunately after 19th months of therapy, tofacitinib had to be discontinued due to significant lymphopenia, which persisted despite dose reduction to 5 mg once daily. The patient was then switched to baricitinib 4 mg once daily, which resulted in a good clinical response, although lymphopenia recurred. There have been multiple case reports on the use of JAKinibs in sarcoidosis, particularly in cases with cutaneous involvement and other inflammatory disorders associated with macrophage activation.[46,47,48,49] Sejournet et al. described a unique case of a patient with both active rheumatoid arthritis and ocular and mediastinal sarcoidosis. [21] The ocular manifestation of sarcoidosis included panuveitis with occlusive retinal vasculitis, macular edema, and nonresolving vitritis. A positron emission tomography scan revealed hypermetabolic mediastinal lymphadenopathy. The patient was steroid‐dependent at a dose of 10 mg/day, with persistent ocular inflammation despite weekly MTX at a dose of 15 mg. Subsequently, tofacitinib 5 mg twice daily was initiated, resulting in a dramatic response in both systemic and ocular manifestations. Complete resolution of vitritis, snowballs, macular edema, and vasculitis was observed.[20] The rationale for using tofacitinib in granulomatous disease arises from the observation that macrophage activation in granulomatous inflammation is dependent on CD4+ cells, which secrete several cytokines such as IL-2 and TNF-α. The JAK1 and JAK3 pathways are known to be constitutively active in sarcoidosis and other granulomatous diseases.[49,50,51] Wang et al.[27] described a case of Behcet’s disease with refractory articular, mucocutaneous, and anterior uveitis. The patient had been on long- term oral steroid therapy combined with colchicine and MTX but developed an opportunistic candidiasis infection. Subsequently, Aza was initiated at a dose of 2 mg/kg/day; however, a relapse of systemic and ocular symptoms occurred upon corticosteroid therapy. The disease activity entered remission with the introduction of tofacitinib 11 mg extended-release once daily, allowing for the successful discontinuation of oral steroid therapy. Tofacitinib monotherapy was maintained for 6 months, during which disease remission was sustained.
Besides the use of JAKinibs in patients with systemic rheumatological diseases associated uveitis, Xiao Bao et al.[23] described the efficacy of tofacitinib in a patient with noninfectious chronic anterior uveitis without systemic involvement. Initially, the patient was treated with systemic corticosteroids but experienced a relapse, requiring biological therapy with adalimumab. Conventional IMT, including MTX, MMF, and cyclosporine A, was added at the time of cataract surgery, while oral corticosteroids were continued at a dose of 20 mg/day. Over 5 years of follow-up, the patient developed corticosteroid-related side effects, including weight gain and hyperglycemia, with persistent uveitis. Subsequently, tofacitinib 5 mg twice daily initiated alongside MTX and low-dose oral prednisolone (20 mg/day), which was eventually tapered to 5 mg/day. At 10 months of follow-up, the uveitis was in remission.
The available data from various case series and case reports emphasize the potential of tofacitinib as an effective intervention for severe and refractory uveitis. It has been shown to serve both as a long-term agent for maintaining anti-inflammatory effects and steroid-sparing benefits, as well as a fast-acting IMT capable of controlling acute inflammation. Paley et al. have reported mixed efficacy of JAK-inhibitors in controlling inflammation, noting that systemic inflammation remained uncontrolled despite optimum therapy.[15] Some reports indicate that tofacitinib may begin to show effects within as little as two weeks after the initial dose, while a response has been observed as early as 3 days in patients with ulcerative colitis.[52,53,54] However, outcomes have been variable; Paley et al. have reported mixed efficacy of JAK inhibitors, with some cases showing uncontrolled systemic inflammation despite optimal therapy. These inconsistencies underscore the need for randomized controlled trials (RCTs) to establish the efficacy and safety of tofacitinib in uveitis.
Baricitinib
Baricitinib preferentially inhibits JAK1 and JAK2 and has been approved for the treatment of rheumatoid arthritis.[55] There are relatively fewer reports on its effect in uveitis. Miserocchi et al.[18] described its use in refractory juvenile idiopathic arthritis-related uveitis, initiating treatment at 4 mg/day in 2 patients and 5 mg/day in 1 patient. All patients had previously received multiple conventional IMTs and biologics. In patient 1, baricitinib 5 mg/day with MTX 15 mg/week induced remission of ocular disease, but polyarthritis remained active, requiring multiple intra-articular steroid injections and oral prednisolone (12.5 mg/day). In patient 2, baricitinib monotherapy was sufficient to resolve both arthritis and uveitis. In patient 3, baricitinib 4 mg/day with MTX 15 mg/week and oral prednisolone 7.5 mg/day resolved uveitis, though arthritis persisted, necessitating a change in therapy. All cases showed uveitis resolution with JAKinib therapy, with the longest follow-up of 13 months and no reported side effects.[18] Álvarez-Reguera et al.[26] also reported the efficacy of baricitinib in a patient with Blau syndrome. However, the patient developed lymphopenia after 4 months of therapy. Kaneko et al.[22] reported a case of seronegative rheumatoid arthritis with severe joint involvement and panuveitis that was refractory to a combination of MTX (12 mg/week), salazosulfapyridine (1,000 mg/day), and Ada (40 mg/subcutaneously every 2 weeks). When Ada was switched to infliximab (3–6 mg/kg intravenous infusion, inflammation persisted despite 42 months of therapy. The patient was then shifted to baricitinib (8 mg/day), leading to the resolution of corneal infiltrates, anterior chamber cells, and macular edema within 3 months. This improvement was maintained for 2 years and 7 months of follow-up. Wang et al.[30] published a case series of 17 patients with refractory systemic Behcet’s disease managed with baricitinib. Among them, only one patient had concomitant uveitis, which was resistant to multiple IMT agents, including MTX, azathioprine, cyclophosphamide, tacrolimus, and thalidomide, as well as biologics like etanercept and tocilizumab. Notably, remission was ultimately achieved with a combination of baricitinib, azathioprine, and MTX.
These case reports suggest a potential role for baricitinib in the treatment of severe and refractory uveitis. Further, an ongoing trial investigating the efficacy of baricitinib in JIA-associated uveitis or chronic ANA-positive uveitis (JUVE-BRIGHT) is an important step toward establishing higher-level evidence for its use.[14]
Upadacitinib
Upadacitinib is part of a newer generation of JAKinibs. It is a selective JAK-1-inhibitor. Theoretically, selective JAK-1 inhibitors cause fewer side effects and could have a superior therapeutic effect compared to first-generation JAKinibs.[56,57] Upadacitinib has received FDA approval for conditions such as inflammatory bowel disease, rheumatoid arthritis, and atopic dermatitis. However, its application in ocular diseases has been relatively limited. There are only four documented case reports detailing the use of upadacitinib in uveitis. Schneider et al.[28] reported its use in a case of HLA-B27-positive spondyloarthropathy with intermediate uveitis and macular edema refractory to a combination of steroids and adalimumab. Upadacitinib was started at 15 mg/day, which led to remission and maintenance of remission of inflammation at 8 months of follow-up without any serious adverse effects. The rationale for including upadacitinib was its reported use in patients with ankylosing spondylitis, with a numerical reduction in the development of uveitis in patients treated with upadacitinib compared to those treated with placebo.[58] Baquet-Walscheid et al.[34] reported the use of upadacitinib in a case of bilateral non-necrotizing anterior and posterior scleritis associated with axial spondyloarthropathy, psoriasis, and IgA nephritis. The scleritis was refractory to MTX, azathioprine, cyclosporine A, infliximab, rituximab, golimumab, and Ada in various combinations. Upon initiating upadacitinib 15 mg/day, remission was noted after 1 week of monotherapy and was maintained without any adverse effects. The same group has also published another case report on the successful use of upadacitinib in a patient with JIA who had an inadequate response to multiple IMT drugs, including tofacitinib. The disease remained in remission with a combination of tofacitinib 5 mg twice daily and MTX 7.5 mg/10 days. However, when MTX had to be discontinued due to adverse effects, tofacitinib monotherapy proved ineffective in sustaining remission. However, upadacitinib 15 mg/day was sufficient to maintain remission.[32] This is promising, as it suggests that switching to a more selective JAKinibs may be beneficial for patients refractory to other JAKinibs while also providing a better safety profile.[59] Tao et al.[31] reported two cases of Behcet’s disease that did not respond to a combination of oral steroids, mycophenolate mofetil, cyclosporine A, and adalimumab. In both patients, Ada was replaced with upadacitinib while the other treatments were continued. Resolution of inflammation was noted in both cases, while one patient experienced transient mild leukopenia and transaminitis as adverse effects.
In conclusion, newer generations of selective JAKinibs offer potential benefits in achieving remission with fewer side effects, even in cases refractory to conventional JAKinibs. However, further randomized control trials with longer follow-ups are needed to establish their efficacy and safety profiles.
Safety concerns
In a recent RCT published in the New England Journal of Medicine, tofacitinib was compared with a TNF inhibitor in patients with rheumatoid arthritis who belonged to a cardiovascular risk-enriched population (age over 50 years with at least one additional cardiovascular risk factor). It was observed that the risks of major adverse cardiovascular events and cancers were higher in those treated with tofacitinib. The authors also concluded that the incidence of adjudicated opportunistic infections were higher with tofacitinib, while efficacy was comparable.[60,61] This has led to a black box warning by the FDA for tofacitinib, baricitinib, and upadacitinib.[62,63] However, it is also important to understand that patients with rheumatoid arthritis, due to the underlying inflammatory processes, are at a higher risk of these comorbidities, and further trials are needed to clarify the real role of JAKinibs in controlling or inducing these complications.[64,65] Notably, no clinical trials have been conducted in patients with uveitis to monitor safety. Manoharan et al.[66] reported a case of branch retinal vein occlusion in a 47- year-old patient with hypertension and rheumatoid arthritis who was started on tofacitinib for non-necrotizing scleritis. Here again, the patient belonged to a risk-enriched population.
The risk of opportunistic infections, especially herpes zoster infection, is also higher with tofacitinib. Using epidemiological health plan data, patients with no previous history of herpes simplex or zoster who were started on tofacitinib and other biologics were compared. The study concluded that the rate of zoster with tofacitinib was almost double that of other biologics.[67] This risk is also dose-dependent.[68] Sunzini et al.[69] concluded that rheumatic musculoskeletal disorders, such as rheumatoid arthritis, result in immunocompromise due to the underlying disease as well as the various immunomodulatory therapies used for disease control, which may lead to opportunistic infections. As mentioned earlier, the unique capability of JAKinibs to simultaneously inhibit the activity of multiple cytokines is likely why they are effective in treating diseases that do not respond to conventional IMT and biologics. This same ability may also explain the increased risk of herpes infections associated with their use.[69] Although the risk of zoster infection appears to be similar for the different JAKinibs, inhibition of JAK2 and JAK3 may lead to a higher risk of zoster infection, while selectivity for JAK1 may lead to a lower risk.[69] Currently, there is no evidence from existing case reports or series to suggest that JAK inhibitors increase susceptibility to tuberculosis. A case series by Pyare et al., which included 10 patients with scleritis treated in a tuberculosis-endemic South Asian center, did not report any cases of systemic tuberculosis reactivation.[24] However, given the small sample size, larger studies are needed to better understand the impact of JAK inhibitor selectivity on infection risk, particularly in tuberculosis-endemic settings. The American College of Rheumatology recommends that patients receive the live zoster vaccine at least 2 weeks prior to starting biologics or tofacitinib therapy, as well as undergo screening for tuberculosis.[70] Álvarez-Reguera et al.[26] noted lymphopenia while using both tofacitinib and baricitinib. Similarly, Tao et al.[31] reported mild leukopenia and transaminitis with upadacitinib; however, the effect was transient and reversed without a change in dosage, with the addition of liver-protecting Chinese herb administration during the last 5 months of follow up.
Upcoming molecules and their trials as potential agents in the future
Filgotinib
Filgotinib has been reported to selectively inhibit JAK1, and it has been approved for the treatment of rheumatoid arthritis in the European Union and Japan in adult patients who have responded inadequately to or are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).[71] There is limited literature discussing the role of filgotinib in NIU. Animal studies in an endotoxin-induced uveitis model in rats concluded that filgotinib is a potential alternative treatment option for preventing the development of NIU.[72] Subsequently, the HUMBOLDT trial assessed the safety and efficacy of filgotinib in patients with active noninfectious intermediate uveitis, posterior uveitis, and panuveitis despite 2 weeks of systemic corticosteroid therapy.[37] It was a double-masked, placebo-controlled, randomized clinical trial with a total of 38 participants receiving filgotinib at a dose of 200 mg orally for 52 weeks and 36 participants on placebo. The trial was terminated early due to business reasons unrelated to the efficacy or safety of filgotinib. Despite its early termination, the trial concluded that filgotinib lowered the risk of treatment failure in patients with NIU, with 37.5% of patients in the filgotinib group experiencing treatment failure by 24 weeks of therapy compared to 67.6% in the placebo group. However, the premature termination of the trial precluded the collection of further safety data in patients being treated with filgotinib.
Brepocitinib
Brepocitinib is a dual inhibitor of tyrosine kinase 2 (TYK2) and JAK1, with once-daily oral dosing. The NEPTUNE study, a phase 2 doubled-blinded RCT, evaluated the safety and efficacy of oral brepocitinib in two different doses (45 mg and 15 mg) in adults with active NIU.[73] The interim 24-week results were presented at the American Society of Retina Specialists annual meeting in July 2024 and the annual meeting of the American Academy of Ophthalmology in October 2024, demonstrating a statistically significant reduction in the treatment failure rate (29.4% with 45 mg; 44.4% with 15 mg) compared to the pre-specified historical placebo-related treatment failure rate of 80%.[74,75] There was evidence of a dose-response, with better outcomes observed with the 45 mg dosage and a similar adverse event rate. Currently, the CLARITY trial, a phase 3 randomized, double-blinded, placebo controlled study, is recruiting patients with NIU to evaluate oral brepocitinib 45 mg for NIU.[76]
Others
Ruxolitinib is a reversible JAK1 and JAK2 tyrosine kinases inhibitor. It has been approved for the treatment of myelofibrosis and polycythemia vera. Ruxolitinib has been successfully used to alleviate experimentally induced uveitis (EIU) in rat models by inhibiting the JAK2-STAT3 pathway.[77] In practical application, this molecule has not been used for uveitis. Abrocitinib is a reversible, selective JAK1 inhibitor that is administered orally at a dose of 100–200 mg/day. It has been approved for the treatment of atopic dermatitis; however, its use for NIU has been limited, with a single case report describing its use in tattoo granuloma with uveitis (TAGU).[78]
Conclusion
In conclusion, JAKinibs, like tofacitinib, baricitinib, Upadacitinib, and filgotinib, represent an exciting new frontier in the management of uveitis, especially severe and refractory cases. The existing literature, although predominantly composed of case reports and case series, highlights the potential efficacy of these drugs in controlling uveitic inflammation. However, safety concerns, such as increased cardiovascular risks and opportunistic infections, underscore the need for further research to establish their safety and efficacy profiles. The emergence of newer JAK inhibitors, like peficitinib and ruxolitinib, presents additional avenues of treatment. Further randomized controlled trials are necessary to cement the role of these agents in uveitis.
Key learning points
JAKinibs may be considered for patients with NIU refractory to conventional and biological IMT as an orally administered small-molecule synthetic drug.
Before initiating JAKinib therapy, screening for latent tuberculosis and viral infections (HIV, hepatitis B, and hepatitis C) is essential. Baseline investigations, including a complete blood count, liver function tests, and kidney function tests, should be conducted and repeated every 3 months during.
Tofacitinib is the most commonly used JAKinib. The dosage is weight-dependent. The dose in patients with weight > 40 kg is 5 mg twice daily or 11 mg extended-release once daily, while for patients with weight between 20 and 40 kg, the dose is 4 mg twice daily. The dose for patients with weight between 10 and 20 kg is 3.2 mg twice daily (oral suspension, 1 mg/ml).[79]
Unlike tofacitinib, baricitinib dosage is age-dependent, with dose being 2 mg once daily for age <6 years and 4 mg once daily for age >6 years. Upadacitinib is used at 15 mg once daily, while filgotinib is dosed at 200 mg/day.
Patients should be monitored for clinical response and adverse events every 4–6 weeks.
Conflicts of interest
There are no conflicts of interest.
Funding Statement
Nil.
References
- 1.Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in inflammatory and autoimmune diseases. Bio Drugs Clin Immunother Biopharm Gene Ther. 2019:3315–32. doi: 10.1007/s40259-019-00333-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Luger D, Silver PB, Tang J, Cua D, Chen Z, Iwakura Y, et al. Either a Th17 or a Th1 effector response can drive autoimmunity: Conditions of disease induction affect dominant effector category. J Exp Med. 2008;205:799–810. doi: 10.1084/jem.20071258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): A multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet Lond Engl. 2016;388:1183–92. doi: 10.1016/S0140-6736(16)31339-3. [DOI] [PubMed] [Google Scholar]
- 4.Jaffe GJ, Dick AD, Brézin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in Patients with Active Noninfectious Uveitis. N Engl J Med. 2016;375:932–43. doi: 10.1056/NEJMoa1509852. [DOI] [PubMed] [Google Scholar]
- 5.Bartelds GM, Krieckaert CLM, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JWR, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460–8. doi: 10.1001/jama.2011.406. [DOI] [PubMed] [Google Scholar]
- 6.Damsky W, Peterson D, Ramseier J, Al-Bawardy B, Chun H, Proctor D, et al. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. J Allergy Clin Immunol. 2021;147:814–26. doi: 10.1016/j.jaci.2020.10.022. [DOI] [PubMed] [Google Scholar]
- 7.Huang Z, Jiang Q, Chen J, Liu X, Gu C, Tao T, et al. Therapeutic effects of upadacitinib on experimental autoimmune uveitis: Insights from single-cell analysis. Invest Ophthalmol Vis Sci. 2023;64:28. doi: 10.1167/iovs.64.12.28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Bing SJ, Lyu C, Xu B, Wandu WS, Hinshaw SJ, Furumoto Y, et al. Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Mol Vis. 2020;26:641–51. [PMC free article] [PubMed] [Google Scholar]
- 9.Takase H, Yu CR, Liu X, Fujimoto C, Gery I, Egwuagu CE. Induction of suppressors of cytokine signaling (SOCS) in the retina during experimental autoimmune uveitis (EAU): Potential neuroprotective role of SOCS proteins. J Neuroimmunol. 2005;168:118–27. doi: 10.1016/j.jneuroim.2005.07.021. [DOI] [PubMed] [Google Scholar]
- 10.He C, Yu CR, Sun L, Mahdi RM, Larkin J, Egwuagu CE. Topical administration of a suppressor of cytokine signaling-1 (SOCS1) mimetic peptide inhibits ocular inflammation and mitigates ocular pathology during mouse uveitis. J Autoimmun. 2015;62:31–8. doi: 10.1016/j.jaut.2015.05.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Wen J, Hu H, Chen M, Yang H, Zhao Y, Liu Y. Role of janus kinase (JAK) inhibitor in autoimmune ocular inflammation: A systematic review. J Immunol Res. 2021;2021:2324400. doi: 10.1155/2021/2324400. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Lv Y, Mi P, Babon JJ, Fan G, Qi J, Cao L, et al. Small molecule drug discovery targeting the JAK-STAT pathway. Pharmacol Res. 2024;204:107217. doi: 10.1016/j.phrs.2024.107217. [DOI] [PubMed] [Google Scholar]
- 13.Maccora I, Land P, Miraldi Utz V, Angeles-Han ST. Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis. Expert Rev Clin Immunol. 2023;19:689–92. doi: 10.1080/1744666X.2023.2207823. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ramanan AV, Guly CM, Keller SY, Schlichting DE, de Bono S, Liao R, et al. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: Study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT) Trials. 2021;22:689. doi: 10.1186/s13063-021-05651-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019;13:53–5. doi: 10.1016/j.ajoc.2018.12.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27:1232–4. doi: 10.1080/09273948.2019.1605453. [DOI] [PubMed] [Google Scholar]
- 17.Fabiani C, Sota J, Sainz-de-la-Maza M, Pelegrín L, Emmi G, Lopalco G, et al. New potential weapons for refractory scleritis in the era of targeted therapy. Mediators Inflamm. 2020;2020:8294560. doi: 10.1155/2020/8294560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Miserocchi E, Giuffrè C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39:847–51. doi: 10.1007/s10067-019-04875-w. [DOI] [PubMed] [Google Scholar]
- 19.Pyare R, Kaushik V, Majumder PD, Biswas J. Tofacitinib in recalcitrant scleritis: First case report from India. Indian J Ophthalmol. 2020;68:1988. doi: 10.4103/ijo.IJO_534_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Dutta Majumder P, Shah A, Kaushik V. Tofacitinib in Vogt-Koyanagi-Harada disease. Indian J Ophthalmol. 2020;68:1938–9. doi: 10.4103/ijo.IJO_998_20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Sejournet L, Kodjikian L, Grange L, Grumet P, Jamilloux Y, Seve P. Resolution of ocular and mediastinal sarcoidosis after Janus kinase inhibitor therapy for concomitant rheumatoid arthritis. Clin Exp Rheumatol. 2021;39:225–6. doi: 10.55563/clinexprheumatol/3gymd4. [DOI] [PubMed] [Google Scholar]
- 22.Kaneko Y, Murakami T, Nishitsuka K, Takakubo Y, Takagi M, Yamashita H. Effectiveness of baricitinib in refractory seronegative rheumatoid arthritis and uveitis: A case report. Front Med. 2021;8:764067. doi: 10.3389/fmed.2021.764067. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Liu XB, Tang LS, Chen JW, Lin CS, Liu QH, Xu Q. Case report: A promising treatment strategy for noninfectious uveitis. Front Pharmacol. 2021;12:784860. doi: 10.3389/fphar.2021.784860. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Pyare R, Dutta Majumder P, Shah M, Kaushik V, Agarwal M, Biswas J. Tofacitinib in scleritis: A case series. Ocul Immunol Inflamm. 2024;32:884–90. doi: 10.1080/09273948.2022.2113805. [DOI] [PubMed] [Google Scholar]
- 25.Baisya R, Gavali M, Tyagi M, Devarasetti PK. A case of SAPHO syndrome complicated by uveitis with good response to both TNF inhibitor and JAKinib. Case Rep Rheumatol. 2023;2023:6201887. doi: 10.1155/2023/6201887. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Álvarez-Reguera C, Prieto-Peña D, Herrero-Morant A, Sánchez-Bilbao L, Martín-Varillas JL, González-López E, et al. Clinical and immunological study of tofacitinib and baricitinib in refractory blau syndrome: Case report and literature review. Ther Adv Musculoskelet Dis. 2022;14:1759720X221093211. doi: 10.1177/1759720X221093211. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Wang CR, Wong TW, Hsu SM. Extended-release tofacitinib for refractory Behçet disease: A case report. Medicine (Baltimore) 2022;101:e29189. doi: 10.1097/MD.0000000000029189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Schneider J, Schalenbourg A, Dudler J, Guex-Crosier Y. Intermediate uveitis in an HLA-B27-positive patient treated with upadacitinib. Klin Monatsbl Augenheilkd. 2022;239:572–4. doi: 10.1055/a-1766-6739. [DOI] [PubMed] [Google Scholar]
- 29.Babu K, Mooss V, Rao AP. Tofacitinib in juvenile idiopathic arthritis-associated uveitis. Indian Journal of Ophthalmology - Case Reports. 2022;2:911–2. [DOI: 10.4103/ijo.IJO_789_22] [Google Scholar]
- 30.Wang Z, Wang X, Liu W, Wang Y, Liu J, Zhang L, et al. Baricitinib for the treatment of refractory vascular Behçet’s disease. Clin Immunol Orlando Fla. 2023;250:109298. doi: 10.1016/j.clim.2023.109298. [DOI] [PubMed] [Google Scholar]
- 31.Tao T, He D, Peng X, Huang Z, Su W. Successful remission with upadacitinib in two patients with anti-TNF-refractory macular edema associated with behçet’s uveitis. Ocul Immunol Inflamm. 2024;32:1897–900. doi: 10.1080/09273948.2023.2263557. [DOI] [PubMed] [Google Scholar]
- 32.Baquet-Walscheid K, Heinz C, Rath T, Scheel M, Heiligenhaus A. Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: A case report. Ocul Immunol Inflamm. 2023;31:1079–80. doi: 10.1080/09273948.2022.2069128. [DOI] [PubMed] [Google Scholar]
- 33.Dey S, Sarkar R, Pradhan A, Padhan P, Maikap D. Tofacitinib in refractory scleritis: A case series. Mediterr J Rheumatol. 2023;34:367–71. doi: 10.31138/mjr.20230828.ti. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Baquet-Walscheid K, Heinz C, Heiligenhaus A. Beneficial effect of upadacitinib in a refractory course of scleritis: A case report. Ocul Immunol Inflamm. 2024;32:1076–8. doi: 10.1080/09273948.2022.2145488. [DOI] [PubMed] [Google Scholar]
- 35.Vitale A, Palacios-Olid J, Caggiano V, Ragab G, Hernández-Rodríguez J, Pelegrín L, et al. Efficacy and safety of Janus kinase inhibitors in non-infectious inflammatory ocular diseases: A prospective cohort study from the international AIDA network registries. Front Med. 2024;11:1439338. doi: 10.3389/fmed.2024.1439338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Dutta Majumder P, Abraham S, Sudharshan S, Janarthanan M, Ramanan AV. Tofacitinib for refractory uveitis and scleritis in children: A case series. Ocul Immunol Inflamm. 2024;32:2092–5. doi: 10.1080/09273948.2024.2323671. [DOI] [PubMed] [Google Scholar]
- 37.Srivastava SK, Watkins TR, Nguyen QD, Sharma S, Scales DK, Dacey MS, et al. Filgotinib in Active Noninfectious Uveitis: The HUMBOLDT randomized clinical trial. JAMA Ophthalmol. 2024;142:789–97. doi: 10.1001/jamaophthalmol.2024.2439. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Hall S, Nash P, Rischmueller M, Bossingham D, Bird P, Cook N, et al. Tofacitinib, an oral janus kinase inhibitor: Pooled efficacy and safety analyses in an australian rheumatoid arthritis population. Rheumatol Ther. 2018;5:383–401. doi: 10.1007/s40744-018-0118-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495–507. doi: 10.1056/NEJMoa1109071. [DOI] [PubMed] [Google Scholar]
- 40.van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508–19. doi: 10.1056/NEJMoa1112072. [DOI] [PubMed] [Google Scholar]
- 41.Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017;377:1537–50. doi: 10.1056/NEJMoa1615975. [DOI] [PubMed] [Google Scholar]
- 42.Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–36. doi: 10.1056/NEJMoa1606910. [DOI] [PubMed] [Google Scholar]
- 43.Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, et al. Tofacitinib in juvenile idiopathic arthritis: A double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet Lond Engl. 2021;398:1984–96. doi: 10.1016/S0140-6736(21)01255-1. [DOI] [PubMed] [Google Scholar]
- 44.Liu X, Jiang Q, Lv J, Yang S, Huang Z, Duan R, et al. Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease. JCI Insight. 2022:7e162335. doi: 10.1172/jci.insight.162335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Zhang S, Cai Z, Mo X, Zeng H. Tofacitinib effectiveness in Blau syndrome: A case series of Chinese paediatric patients. Pediatr Rheumatol Online J. 2021;19:160. doi: 10.1186/s12969-021-00634-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Levraut M, Martis N, Viau P, Suarez F, Queyrel V. Refractory sarcoidosis-like systemic granulomatosis responding to ruxolitinib. Ann Rheum Dis. 2019;78:1606–7. doi: 10.1136/annrheumdis-2019-215387. [DOI] [PubMed] [Google Scholar]
- 47.Damsky W, Thakral D, Emeagwali N, Galan A, King B. Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis. N Engl J Med. 2018;379:2540–6. doi: 10.1056/NEJMoa1805958. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. J Am Acad Dermatol. 2020;82:612–21. doi: 10.1016/j.jaad.2019.05.098. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Wang A, Singh K, Ibrahim W, King B, Damsky W. The promise of JAK inhibitors for treatment of sarcoidosis and other inflammatory disorders with macrophage activation: A review of the literature. Yale J Biol Med. 2020;93:187–95. [PMC free article] [PubMed] [Google Scholar]
- 50.Ueki Y, Takimoto-Ito R, Saito MK, Tanizaki H, Kambe N. Tofacitinib, a suppressor of NOD2 expression, is a potential treatment for Blau syndrome. Front Immunol. 2023;14:1211240. doi: 10.3389/fimmu.2023.1211240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Matsuda T, Kambe N, Takimoto-Ito R, Ueki Y, Nakamizo S, Saito MK, et al. Potential benefits of TNF targeting therapy in blau syndrome, a NOD2-associated systemic autoinflammatory granulomatosis. Front Immunol. 2022;13:895765. doi: 10.3389/fimmu.2022.895765. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet Lond Engl. 2013;381:451–60. doi: 10.1016/S0140-6736(12)61424-X. [DOI] [PubMed] [Google Scholar]
- 53.Long MD, Afzali A, Fischer M, Hudesman D, Abdalla M, McCabe R, et al. Tofacitinib response in ulcerative colitis (TOUR): Early response after initiation of tofacitinib therapy in a real-world setting. Inflamm Bowel Dis. 2023;29:570–8. doi: 10.1093/ibd/izac121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Magro F, Estevinho MM. Is tofacitinib a game-changing drug for ulcerative colitis? United Eur Gastroenterol J. 2020;8:755–63. doi: 10.1177/2050640620935732. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Taylor PC, Keystone EC, van der Heijde D, Weinblatt ME, Del Carmen Morales L, Reyes Gonzaga J, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–62. doi: 10.1056/NEJMoa1608345. [DOI] [PubMed] [Google Scholar]
- 56.Akpabio A, Adebajo A. Evaluating upadacitinib for the treatment of psoriatic arthritis. Expert Opin Pharmacother. 2022;23:169–73. doi: 10.1080/14656566.2021.2006183. [DOI] [PubMed] [Google Scholar]
- 57.Kragstrup TW, Glintborg B, Svensson AL, McMaster C, Robinson PC, Deleuran B, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022;8:e002236. doi: 10.1136/rmdopen-2022-002236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Poddubnyy D, Parikh B, Elewaut D, Navarro-Compán V, Siebert S, Paley M, et al. OP0061 development of extra-musculoskeletal manifestations in upadacitinib-treated patients with psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis. Ann Rheum Dis. 2023;82(Suppl 1):40–1. [Google Scholar]
- 59.Traves PG, Murray B, Campigotto F, Galien R, Meng A, Di Paolo JA. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80:865–75. doi: 10.1136/annrheumdis-2020-219012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316–26. doi: 10.1056/NEJMoa2109927. [DOI] [PubMed] [Google Scholar]
- 61.Taylor PC, Weinblatt ME, Burmester GR, Rooney TP, Witt S, Walls CD, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol Hoboken NJ. 2019;71:1042–55. doi: 10.1002/art.40841. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.FDA; 2024. Research C for DE and. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death . [Last accessed on 2024 Dec 07] [Google Scholar]
- 63.Qian J, Xue X, Shannon J. Characteristics of adverse event reporting of Xeljanz/Xeljanz XR, olumiant, and rinvoq to the US food and drug administration. J Manag Care Spec Pharm. 2022;28:1046–52. doi: 10.18553/jmcp.2022.28.9.1046. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Atzeni F, Popa CD, Nucera V, Nurmohamed MT. Safety of JAK inhibitors: Focus on cardiovascular and thromboembolic events. Expert Rev Clin Immunol. 2022;18:233–44. doi: 10.1080/1744666X.2022.2039630. [DOI] [PubMed] [Google Scholar]
- 65.Benucci M, Damiani A, Infantino M, Manfredi M, Lari B, Grossi V, et al. Cardiovascular safety, cancer and Jak-inhibitors: Differences to be highlighted. Pharmacol Res. 2022;183:106359. doi: 10.1016/j.phrs.2022.106359. [DOI] [PubMed] [Google Scholar]
- 66.Manoharan A, Atmakur H, Dutta Majumder P, Biswas J. Branch retinal vein occlusion in a case of recalcitrant diffuse anterior scleritis treated with tofacitinib. J Ophthalmic Inflamm Infect. 2023;13:45. doi: 10.1186/s12348-023-00359-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Curtis JR, Xie F, Yun H, Bernatsky S, Winthrop KL. Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis. Ann Rheum Dis. 2016;75:1843–7. doi: 10.1136/annrheumdis-2016-209131. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Winthrop KL, Curtis JR, Lindsey S, Tanaka Y, Yamaoka K, Valdez H, et al. Herpes zoster and tofacitinib: Clinical outcomes and the risk of concomitant therapy. Arthritis Rheumatol Hoboken NJ. 2017;69:1960–8. doi: 10.1002/art.40189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: Focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1759720X20936059. doi: 10.1177/1759720X20936059. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 70.Singh JA, Saag KG, Bridges SL, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol Hoboken NJ. 2016;68:1–26. doi: 10.1002/art.39480. [DOI] [PubMed] [Google Scholar]
- 71.Su Y, Tao T, Liu X, Su W. JAK-STAT signaling pathway in non-infectious uveitis. Biochem Pharmacol. 2022;204:115236. doi: 10.1016/j.bcp.2022.115236. [DOI] [PubMed] [Google Scholar]
- 72.Erdağ M, Balbaba M, İlhan N, Çalık İ, Ulaş F, Eröksüz Y, et al. Protective effect of filgotinib in rat endotoxin-induced uveitis model. Int Ophthalmol. 2021;41:2905–12. doi: 10.1007/s10792-021-01851-9. [DOI] [PubMed] [Google Scholar]
- 73.Priovant Therapeutics, Inc A Phase 2 Randomized, Double-Masked, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Active Non-Infectious Intermediate-, Posterior-, and Panuveitis. clinicaltrials.gov. 2024. Report No.: NCT05523765. Available from: https://clinicaltrials.gov/study/NCT05523765 . [Last accessed on 2025 Jan 01]
- 74.Wang R. Paper presentation. Stockholm, Sweden: 2024. Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24–Week Results from a 52-Week Phase 2 Study (NEPTUNE) [Google Scholar]
- 75.Nguyen QD. Paper Presentation. Chicago, USA: 2024. Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24–Week Results from a 52-Week Phase 2 Study (NEPTUNE) [Google Scholar]
- 76.Harp MD. First patients enrolled in phase 3 CLARITY trial evaluating brepocitinib in non-anterior non-infectious uveitis. Ophthalmology Times. 2024 [Google Scholar]
- 77.Du L, Yip YWY, Ng HK, Ho BM, He JN, Chan SO, et al. Ruxolitinib alleviates uveitis caused by salmonella typhimurium endotoxin. Microorganisms. 2021;9:1481. doi: 10.3390/microorganisms9071481. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 78.Yang Y, Yan J, Yang J, Wang P, Liu Y, Wang X. Janus kinase inhibitor abrocitinib as an off-Label treatment for tattoo granuloma with uveitis (TAGU) Australas J Dermatol. 2024;65:297–9. doi: 10.1111/ajd.14248. [DOI] [PubMed] [Google Scholar]
- 79.Chang C, Vong C, Wang X, Hazra A, Diehl A, Nicholas T, et al. Tofacitinib pharmacokinetics in children and adolescents with juvenile idiopathic arthritis. CPT Pharmacomet Syst Pharmacol. 2024;13:599–611. doi: 10.1002/psp4.13104. [DOI] [PMC free article] [PubMed] [Google Scholar]
